CpG-insel-hypermethylierung der DNA: Perspektiven eines molekularen biomarkers für das prostatakarzinom

P. J. Bastian; J. Ellinger; A. Von Rücker; S. C. Müller; S. Yegnasubramanian; W. G. Nelson; C. G. Stief

doi:10.1007/s00120-008-1836-9

CpG-insel-hypermethylierung der DNA: Perspektiven eines molekularen biomarkers für das prostatakarzinom

Translated title of the contribution: CpG island hypermethylation of the DNA: Perspectives of a molecular biomarker for prostate cancer

P. J. Bastian, J. Ellinger, A. Von Rücker, S. C. Müller, S. Yegnasubramanian, W. G. Nelson, C. G. Stief

School of Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The exact classification of clinically significant versus insignificant prostate cancer displays one of major problems in current urological practice. Using novel molecular biomarkers, we are trying to decrease overdiagnosis of insignificant cancer. CpG island hypermethylation as a common epigenetic event is a well-recognized phenomenon during carcinogenesis. We have shown that hypermethylation at several gene loci distinguishes between benign and malignant forms of prostatic disorders. Furthermore using tests in cancer tissue and serum samples, one can draw prognostic conclusions and predict biochemical failure following radical prostatectomy with curative intent.

Translated title of the contribution	CpG island hypermethylation of the DNA: Perspectives of a molecular biomarker for prostate cancer
Original language	German
Pages (from-to)	1205-1207
Number of pages	3
Journal	Urologe - Ausgabe A
Volume	47
Issue number	9
DOIs	https://doi.org/10.1007/s00120-008-1836-9
State	Published - Sep 1 2008

Keywords

Biomarker
CpG island
GSTP1
Methylation
Prostate cancer

ASJC Scopus subject areas

Urology

Access to Document

10.1007/s00120-008-1836-9

Cite this

@article{ab493bc9130b489c9fb30d60b897c10d,

title = "CpG-insel-hypermethylierung der DNA: Perspektiven eines molekularen biomarkers f{\"u}r das prostatakarzinom",

abstract = "The exact classification of clinically significant versus insignificant prostate cancer displays one of major problems in current urological practice. Using novel molecular biomarkers, we are trying to decrease overdiagnosis of insignificant cancer. CpG island hypermethylation as a common epigenetic event is a well-recognized phenomenon during carcinogenesis. We have shown that hypermethylation at several gene loci distinguishes between benign and malignant forms of prostatic disorders. Furthermore using tests in cancer tissue and serum samples, one can draw prognostic conclusions and predict biochemical failure following radical prostatectomy with curative intent.",

keywords = "Biomarker, CpG island, GSTP1, Methylation, Prostate cancer",

author = "Bastian, {P. J.} and J. Ellinger and {Von R{\"u}cker}, A. and M{\"u}ller, {S. C.} and S. Yegnasubramanian and Nelson, {W. G.} and Stief, {C. G.}",

year = "2008",

month = sep,

day = "1",

doi = "10.1007/s00120-008-1836-9",

language = "German",

volume = "47",

pages = "1205--1207",

journal = "Urologe - Ausgabe A",

issn = "0340-2592",

publisher = "Springer Verlag",

number = "9",

}

TY - JOUR

T1 - CpG-insel-hypermethylierung der DNA

T2 - Perspektiven eines molekularen biomarkers für das prostatakarzinom

AU - Bastian, P. J.

AU - Ellinger, J.

AU - Von Rücker, A.

AU - Müller, S. C.

AU - Yegnasubramanian, S.

AU - Nelson, W. G.

AU - Stief, C. G.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - The exact classification of clinically significant versus insignificant prostate cancer displays one of major problems in current urological practice. Using novel molecular biomarkers, we are trying to decrease overdiagnosis of insignificant cancer. CpG island hypermethylation as a common epigenetic event is a well-recognized phenomenon during carcinogenesis. We have shown that hypermethylation at several gene loci distinguishes between benign and malignant forms of prostatic disorders. Furthermore using tests in cancer tissue and serum samples, one can draw prognostic conclusions and predict biochemical failure following radical prostatectomy with curative intent.

AB - The exact classification of clinically significant versus insignificant prostate cancer displays one of major problems in current urological practice. Using novel molecular biomarkers, we are trying to decrease overdiagnosis of insignificant cancer. CpG island hypermethylation as a common epigenetic event is a well-recognized phenomenon during carcinogenesis. We have shown that hypermethylation at several gene loci distinguishes between benign and malignant forms of prostatic disorders. Furthermore using tests in cancer tissue and serum samples, one can draw prognostic conclusions and predict biochemical failure following radical prostatectomy with curative intent.

KW - Biomarker

KW - CpG island

KW - GSTP1

KW - Methylation

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=51349089953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51349089953&partnerID=8YFLogxK

U2 - 10.1007/s00120-008-1836-9

DO - 10.1007/s00120-008-1836-9

M3 - Article

C2 - 18651120

AN - SCOPUS:51349089953

SN - 0340-2592

VL - 47

SP - 1205

EP - 1207

JO - Urologe - Ausgabe A

JF - Urologe - Ausgabe A

IS - 9

ER -

CpG-insel-hypermethylierung der DNA: Perspektiven eines molekularen biomarkers für das prostatakarzinom

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this